To Assess The Lower Jaw Fracture Site Bone Density After Using Calcitonin Hormone Spray
Not Applicable
- Conditions
- Health Condition 1: S026- Fracture of mandible
- Registration Number
- CTRI/2023/01/048738
- Lead Sponsor
- Dr Firdous Abdul Sathar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients with isolated mandibular fracture involving symphysis, parasymphysis, body, or angle
2. The age range of 18-50 years
3. Patients categorized as ASA I Status
4. Patients tolerant to the calcitonin nasal spray
Exclusion Criteria
1. Comminuted mandibular fractures
2. Patients with any bony pathologies or thyroid dysfunctions
3. Individuals categorized under ASA II, III, or IV
4. Patients who have negative surgical outcomes such as postoperative malocclusion, interfragmentary mobility, or step deformity
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. To evaluate the efficacy of salmon calcitonin on postoperative pain in mandibular fracture patients. <br/ ><br>2. To assess the change in levels of plasma osteocalcin after administration of salmon calcitonin. <br/ ><br>3. To evaluate the bone density following open reduction and internal fixation of mandibular fractures after administration of salmon calcitonin. <br/ ><br>Timepoint: 1.Visual Analogue Scale on 1st,3rd, and 5th post-operative days. <br/ ><br>2. Serum osteocalcin levels before surgery and after 4 weeks. <br/ ><br>3. Density of bone at fracture site by CBCT scans taken at 2 weeks and 4 weeks postoperatively.
- Secondary Outcome Measures
Name Time Method To assess a better quality of life in these <br/ ><br>patients by fore said parameters.Timepoint: Follow up for 1 month.